Senzime Annual Report 2021

Press release: Uppsala, April 26, 2022. Senzime AB (publ) today announces that the company’s Annual report for year 2021 is now available in Swedish on the company’s website www.senzime.com

Senzime today announces that the company’s Annual report for year 2021 is now available in Swedish on the company’s website https://senzime.com/investor-relations/financial-reports/

For further information, please contact:

Pia Renaudin, CEO of Senzime AB 
Phone: +46 (0) 70-813 34 17, e-mail: [email protected]
 
Slavoljub Grujicic, CFO
Phone: +46 46 (0) 76-306 60 11, e-mail: [email protected]

About Senzime

Senzime is a Swedish medical device company that develops and markets CE- and FDA-cleared monitoring systems for patients undergoing anesthesia. Senzime’s employees worldwide are committed to the vision of a world without anesthesia related complications. Six out of ten patients that wake up after surgery are not fully muscle recovered and therefor at risk having critical respiratory complications. The TetraGraph system helps anesthesia providers improve patient care and reduce healthcare costs by digitally and continuously measure the degree of neuromuscular blockade under and after surgery. Senzime operates in the worlds leading markets targeting a market opportunity valued in excess of SEK 15 billion per year. The company’s shares are listed on Nasdaq Stockholms main market (ticker SEZI). www.senzime.com

This information is information that Senzime is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-04-26 11:25 CEST.

Downloads
Contact

Philip Siberg, CEO of Senzime

+46 (0) 70 790 6734
[email protected]
 

Subscribe

Click here to sign up to our latest news.

Subscription service
en sv de